Johnson & Johnson acquires lumateperone developer in £14.6bn deal
Johnson & Johnson (J&J) has announced the acquisition of Intra-Cellular Therapies for $14.6 billion, marking a significant expansion of its neuroscience portfolio. The deal centres on CAPLYTA (lumateperone), a novel antipsychotic with a distinctive pharmacological profile characterised by high serotonin 5-HT2A receptor occupancy combined with lower dopamine D2 receptor binding at therapeutic doses.